173 related articles for article (PubMed ID: 16724524)
1. [Receptor-mediated Parkinson drugs].
Böckler F
Pharm Unserer Zeit; 2006; 35(3):204-16. PubMed ID: 16724524
[No Abstract] [Full Text] [Related]
2. [History of treatment of Parkinson disease].
Götz W
Pharm Unserer Zeit; 2006; 35(3):190-7. PubMed ID: 16724522
[No Abstract] [Full Text] [Related]
3. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what.
Metman LV; Konitsiotis S; Chase TN
Mov Disord; 2000 Jan; 15(1):3-8. PubMed ID: 10634235
[No Abstract] [Full Text] [Related]
4. Current pharmacotherapeutic treatment options in Parkinson's disease.
Rezak M
Dis Mon; 2007 Apr; 53(4):214-22. PubMed ID: 17586328
[TBL] [Abstract][Full Text] [Related]
5. [Medicinal treatment of idiopathic Parkinson's disease].
Klockgether T
Nervenarzt; 2003 Mar; 74 Suppl 1():S12-21. PubMed ID: 12624679
[TBL] [Abstract][Full Text] [Related]
6. Guideline for the treatment of Parkinson's disease.
Carr J; Kies B; Fine J;
S Afr Med J; 2009 Oct; 99(10):755-6, 758. PubMed ID: 20128276
[No Abstract] [Full Text] [Related]
7. Parkinson's disease and its chemotherapy.
Hornykiewicz O
Biochem Pharmacol; 1975 May; 24(10):1061-5. PubMed ID: 239718
[No Abstract] [Full Text] [Related]
8. Drugs for Parkinson's disease.
Cranwell-Bruce LA
Medsurg Nurs; 2010; 19(6):347-9, 355; quiz 350. PubMed ID: 21337993
[No Abstract] [Full Text] [Related]
9. Basal ganglia, Parkinson's disease and levodopa therapy. Proceedings of a meeting. St Thomas, Virgin Islands, January 2000.
Trends Neurosci; 2000 Oct; 23(10 Suppl):S1-126. PubMed ID: 11221749
[No Abstract] [Full Text] [Related]
10. Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease.
Greenamyre JT
J Neural Transm Gen Sect; 1993; 91(2-3):255-69. PubMed ID: 8099800
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of dopamine inactivating systems as antiparkinson drugs.
Youdim MB
Adv Neurol; 1990; 53():483-8. PubMed ID: 2239488
[No Abstract] [Full Text] [Related]
12. Medications for Parkinson's disease.
Whitney CM
Neurologist; 2007 Nov; 13(6):387-8. PubMed ID: 18090719
[No Abstract] [Full Text] [Related]
13. [Treatment in Parkinson disease].
Takáts A
Orv Hetil; 2004 Apr; 145(15):833-4. PubMed ID: 15188639
[No Abstract] [Full Text] [Related]
14. Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy.
Grace AA
Mov Disord; 2008; 23 Suppl 3():S560-9. PubMed ID: 18781673
[TBL] [Abstract][Full Text] [Related]
15. Role of dopamine receptors in neurological drug treatment.
Rinne UK
Ann Clin Res; 1988; 20(5):334-9. PubMed ID: 3218905
[No Abstract] [Full Text] [Related]
16. Current therapy of Parkinson's disease.
Ajax T; Rodnitzky R; Dobson J
Iowa Med; 1997 Jan; 87(1):27-9. PubMed ID: 9029838
[No Abstract] [Full Text] [Related]
17. [Therapeutic strategies in Parkinson's disease].
Shoulson I
Arch Neurobiol (Madr); 1991; 54(6):277-81. PubMed ID: 1687429
[No Abstract] [Full Text] [Related]
18. Drugs for Parkinson's disease.
Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
[TBL] [Abstract][Full Text] [Related]
19. [Parkinson's disease].
Jean-Luc H
Rev Prat; 2005 May; 55(10):1129-34. PubMed ID: 16097259
[No Abstract] [Full Text] [Related]
20. Prospects of glutamate antagonists in the therapy of Parkinson's disease.
Blandini F; Greenamyre JT
Fundam Clin Pharmacol; 1998; 12(1):4-12. PubMed ID: 9523179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
